poisar

Stock

AstraZeneca PLC AZN

$166.02+0.93%

Overview

AZN market data

Price History

AZN price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
25.18
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$6.55
Diluted earnings per share over the trailing twelve months.
Beta
1.39
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
199.1%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$10,180.00 – $15,730.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $195.6K · P/B 5.86 · P/S 4.33.

Company news

10 captured
AstraZeneca's Enhertu Receives EU Approval Recommendation To Treat Unresectable Or Metastatic HER2-Positive Breast CancerBenzinga · Jul 24, 2026, 11:50 AM
AstraZeneca's Etcamah Receives EU Approval To Treat Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic BreastBenzinga · Jul 23, 2026, 1:58 PM
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La LettreBenzinga · Jul 17, 2026, 6:04 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ DealsGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM
Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To OsimertinibBenzinga · Jul 15, 2026, 12:38 PM
Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments AcceleratesGlobenewswire Inc · Jul 15, 2026, 11:15 AM
AstraZeneca shares are trading lower after the company announced it entered into an exclusive global license agreement with Dizal, where it will pay $600 million upfront and up to $900 million in milestones and royalties.Benzinga · Jul 14, 2026, 7:52 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock